Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in peritoneal dialysis: effects on peritoneal ultrafiltration and residual kidney function
ChiCTR2400088818Phase 2Not yet recruiting
- Sponsor
- Army Medical Center of PLA
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of dapagliflozin in end-stage kidney disease (ESKD) and peritoneal dialysis dependence (PDD) (2 arms), sponsored by Army Medical Center of PLA. Primary endpoint: Peritoneal ultrafiltration volume. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
end-stage kidney disease (ESKD)peritoneal dialysis dependence (PDD)
Beyond the preview
Go deeper on ChiCTR2400088818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088818.